ERYDEL
Summary
EryDel SpA is a global late-stage biotech company aimed at developing and commercializing therapies for the treatment of rare diseases delivered by its proprietary red blood cell technology.
Deals Overview
Total Deals1
Valued Deals1
Total Value£ 419 M
Avg. Deal Size£ 419 M
All rights reserved. Copyright © 2025 Datasite
